<DOC>
	<DOC>NCT02405780</DOC>
	<brief_summary>The purpose of the study is to compare the safety, effectiveness and immunogenicity of FKB327 in comparison to Humira® in rheumatoid arthritis patients who have completed study FKB327-002 and have inadequate disease control on methotrexate.</brief_summary>
	<brief_title>A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1. Patient has completed the Week 24 visit procedures of Study FKB327002 and are continuing with methotrexate 2. In the investigator's opinion, the patient showed a clinical response to treatment during Study FKB327002 1. Patient has evidence of a serious adverse event (SAE) ongoing from Study FKB327002 2. Patient has presence of active and/or untreated latent tuberculosis (TB) Other Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Rheumatoid</keyword>
	<keyword>Arthritis</keyword>
</DOC>